Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

Emad - Elquza, Hani M. Babiker, Krisha J. Howell, Andrew I. Kovoor, Thomas David Brown, Hitendra Patel, Steven A. Malangone, Mitesh J. Borad, Tomislav Dragovich

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalCancer Investigation
Volume34
Issue number2
DOIs
StatePublished - Feb 7 2016

Keywords

  • cisplatin
  • gastroesophageal carcinoma
  • Pemetrexed
  • radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas'. Together they form a unique fingerprint.

  • Cite this